fda semaglutide shortage resolved february 21 2025 declaratory order 2025-2026 has been the wildest two GLP-1 Shortage = Over -

usually mild-to-moderate and easing over time [1]

Phase 2 clinical trial results published in The New England Journal of Medicine demonstrated unprecedented weight loss outcomes, generating significant interest among researchers, clinicians, and individuals seeking effective metabolic interventions

Biller, B

These studies will not only inform clinical development in obesity, but together with recent cardiometabolic data they will also enable multiple paths towards treating patients with cardiovascular disease

Various dairy-derived ingredients like micellar casein, beta-lactoglobulin, and milk oligosaccharides are being explored for creating GLP-1-friendly food

Next Steps If you are battling obesity or managing heart health, semaglutide might be a topic to discuss during your next visit with your healthcare provider